Ivermectin and Cancer: What the Research Actually Shows

I’m not a doctor. I’m a Stage IV cancer patient who reads research, asks questions, and tries to make sense of the noise. Everything here is my experience and my interpretation of the evidence. Talk to your oncologist before changing anything about your treatment.

Now – Ivermectin.

If you’ve spent any time in cancer patient communities, you’ve seen the posts. Someone shares an article about ivermectin killing cancer cells. Someone else swears their uncle’s tumours shrank. Someone links to a Joe Rogan clip. And underneath it all, a question that deserves a real answer: is there anything to this?

I’ve spent months reading the papers. Not the headlines, not the Reddit threads – the actual published research. There are 429 studies on PubMed mentioning ivermectin and cancer as of April 2026. I’m going to walk you through what they say, what they don’t, and where this honestly stands.

---

Why People Are Talking About Ivermectin and Cancer

Ivermectin won the Nobel Prize in 2015. Not for cancer – for treating river blindness and lymphatic filariasis. William Campbell and Satoshi Omura discovered it in the 1970s, and since then it’s been given to roughly 250 million people a year as an antiparasitic. Its safety profile across billions of doses is well established.

The cancer interest started in research labs. Scientists studying ivermectin’s effects noticed it could kill cancer cells in petri dishes – through mechanisms completely unrelated to its antiparasitic action. That was interesting enough to publish, and papers started accumulating.

Then two things happened that turned a niche research topic into a cultural phenomenon.

First, a man called Joe Tippens went public with his story. Diagnosed with small cell lung cancer in 2016, he began taking fenbendazole – a related antiparasitic drug, but one designed for dogs – alongside supplements. His cancer went into remission. The story went viral, particularly in South Korea, and spawned the “Joe Tippens Protocol.”

Here’s the critical detail most fenbendazole content leaves out: Tippens was simultaneously enrolled in a clinical trial for Keytruda (pembrolizumab), a PD-L1 checkpoint inhibitor immunotherapy. Keytruda is known to produce complete responses in some patients. His remission cannot be attributed to fenbendazole alone. This is a single case, not evidence.

Second, COVID happened. Ivermectin became a political flashpoint, and the polarisation made it nearly impossible to discuss the drug rationally for any purpose. That polarisation still clouds the cancer conversation today. Mainstream media often treats ivermectin as inherently suspect. Proponents treat scepticism as conspiracy. Neither helps patients trying to make informed decisions.

I have no political position on ivermectin. I have a cancer. And ivermectin is one of several antiparasitics I use as part of my Stage IV protocol – alongside mebendazole and fenbendazole, rotated in blocks following Jane McLelland’s Metro Map framework. So this isn’t abstract for me.

---

What the Laboratory Evidence Says

The preclinical research is genuinely interesting. Not “cure for cancer” interesting – but “this warrants proper investigation” interesting. Dr William Makis, a Canadian nuclear medicine physician, has catalogued at least 15 distinct anti-cancer mechanisms from the published literature. I’ll cover the six I consider most significant.

1. Autophagy Induction (PAK1/Akt/mTOR Pathway)

Ivermectin promotes degradation of a protein called PAK1, which blocks the Akt/mTOR signalling cascade. The result: cancer cells undergo excessive self-digestion (autophagy) beyond their survival capacity. Crucially, this preferentially affects cancer cells while largely sparing healthy tissue (Dou et al., Cancer Research, 2016).

2. WNT/Beta-Catenin Pathway Inhibition

The WNT pathway is overactive in many cancers, especially colorectal, breast, and lung. Ivermectin blocks WNT-TCF signalling, reducing cancer cell proliferation and suppressing a process called epithelial-to-mesenchymal transition (EMT) – which is how cancer cells learn to spread (Melotti et al., EMBO Molecular Medicine, 2014; Jiang et al., American Journal of Cancer Research, 2022).

3. Mitochondrial Dysfunction

Ivermectin inhibits mitochondrial complex I in cancer cells, dramatically reducing their energy production. This triggers oxidative stress and accelerates cell death (Tang et al., Pharmacological Research, 2021).

4. Cancer Stem Cell Targeting

Cancer stem cells are responsible for tumour recurrence, metastasis, and treatment resistance. Ivermectin preferentially inhibits these stem-like populations, downregulating key genes including NANOG, SOX2, and OCT4. In breast cancer models, it showed superior activity against CD44+/CD24- stem-like cells (Dominguez-Gomez et al., Molecular Medicine Reports, 2018).

5. Anti-Metastatic Effects

By suppressing WNT/beta-catenin/integrin beta1/FAK signalling and reducing MMP-9 expression (an enzyme involved in tumour invasion), ivermectin inhibits cancer cell migration (Jiang et al., 2022).

6. Immune Modulation

A 2026 study by Draganov et al. found ivermectin may convert immunologically “cold” tumours (invisible to the immune system) into “hot” tumours (recognisable), potentially synergising with immune checkpoint inhibitors. This is early but genuinely compelling if it translates to humans.

The honest summary: These are real biological effects, published in legitimate journals, by serious researchers. Most are from cell cultures and animal models, which is where mainstream oncology draws the line. As Dr John Mafi of UCLA put it in March 2026: “Most promising drugs in test tubes and mice don’t pan out in humans.” That’s statistically true. But as Dr Marik and others argue, the sheer breadth of mechanisms – across multiple cancer types and pathways – combined with ivermectin’s established safety profile in humans, makes it a stronger candidate for repurposing than most drugs at this stage.

If you want to understand how these pathways fit into the broader metabolic picture, I wrote about metabolic medicine and integrative oncology – the framework I use to evaluate approaches like this.

---

What the Human Evidence Actually Shows

This is where it gets sobering.

As of April 2026, there are no completed large-scale randomised controlled trials of ivermectin for cancer in humans. Zero.

The Cedars-Sinai Trial (NCT05318469)

The most advanced human trial is a Phase I/II study at Cedars-Sinai, testing ivermectin combined with immune checkpoint inhibitors (balstilimab or pembrolizumab) for metastatic triple-negative breast cancer.

Preliminary results were presented at ASCO 2025. Of 8 evaluable patients: 1 partial response, 1 stable disease, 6 progressive disease. No significant benefit from adding ivermectin was observed.

This is one small trial with one cancer type and one combination. It doesn’t prove ivermectin doesn’t work. It does prove that the first proper human test didn’t produce the results the lab data suggested it might.

The NCI Study

In January 2026, NCI Director Anthony Letai announced the National Cancer Institute would conduct preclinical studies on ivermectin’s ability to kill cancer cells. Results are expected mid-2026. His own framing was measured: “At least on a population level, it’s not going to be a cure-all for cancer.”

The decision alarmed some career NCI scientists, who called it “absurd.” The political context – Florida’s $60 million cancer research funding including ivermectin studies, five US states making it available over the counter – makes this a charged space. But the NCI’s involvement signals that the question is being taken seriously at institutional level.

The Kory Case Series

Dr Pierre Kory, formerly of Rebuild Medicine (now Leading Edge Clinic), published a 5-patient case series in January 2026. All had metastatic lung cancer. All received a combination protocol: ivermectin, mebendazole, metformin, propranolol, low-dose naltrexone, doxycycline, a ketogenic diet, plus supplements. If some of those drug names look familiar, it’s because several overlap with the approach I detail in my protocol write-up – particularly Pillar 4 on repurposed antiparasitics.

The outcomes were striking – one complete remission (in a patient also on alectinib), stable disease in patients expected to decline, maintained quality of life across the board.

But Kory himself acknowledges the limitations: 5 patients, multi-drug protocols (impossible to isolate ivermectin’s contribution), selection bias, no randomisation, no control group, no blinding. These are case reports, not clinical trials. They generate hypotheses. They don’t prove anything.

The Marik Cancer Care Protocol

Dr Paul Marik – formerly chief of pulmonary and critical care medicine at Eastern Virginia Medical School, now chief scientific officer at the Independent Medical Alliance (formerly FLCCC) – has produced something that deserves serious attention.

His Cancer Care monograph (2nd edition, October 2024) reviews over 2,000 peer-reviewed papers on repurposed drugs for cancer. Ivermectin is one component of a broader metabolic protocol that includes mebendazole, fenbendazole, metformin, propranolol, doxycycline, high-dose vitamin C, curcumin, and others. If that list looks familiar, it’s because my own protocol draws from the same evidence base.

Marik frames this explicitly as adjunctive therapy – alongside standard oncological treatment, not replacing it. His inclusion criteria for any drug in the monograph require evidence of cancer cell killing, cancer stem cell inhibition, favourable effects on the tumour microenvironment, and a reasonable safety profile.

In February 2024, the IMA launched a 500-patient observational study examining 5-year survival rates for breast, prostate, lung, and colorectal cancer patients using repurposed drug regimens. Results have not yet been published, but this is the largest systematic attempt to track outcomes in this space.

The Makis-Marik MSCC Paper

In September 2024, Dr Makis and Dr Marik co-authored a peer-reviewed paper with a team of researchers: “Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol” (Baghli et al., Journal of Orthomolecular Medicine, 2024).

The paper introduces the Mitochondrial-Stem Cell Connection (MSCC) theory – that cancer originates from chronic oxidative phosphorylation insufficiency in stem cells, creating cancer stem cells (CSCs) with abnormal energy metabolism. Their argument: standard therapies target bulk cancer cells but fail to eliminate CSCs, which is why cancers recur. They cite Ladanie et al.’s finding that new anticancer therapies over the past 15 years have improved overall survival by only 2.4 months on average.

The protocol targets cancer through multiple simultaneous pathways – enhancing oxidative phosphorylation, cutting off glucose and glutamine fuel supplies, and directly targeting cancer stem cells. This is essentially the same metabolic logic that underpins Jane McLelland’s Metro Map, which I use to structure my own approach.

Important context: The Journal of Orthomolecular Medicine is peer-reviewed but is not a mainstream oncology journal. The MSCC theory is a hypothesis, not established oncological consensus. But the mechanistic reasoning is grounded in published research, and the approach is gaining traction among integrative oncologists.

---

Ivermectin vs Fenbendazole vs Mebendazole

If you’re researching antiparasitic drugs for cancer, you’ll encounter all three. Here’s how they compare.

	Ivermectin	Fenbendazole	Mebendazole
Drug class	Avermectin derivative	Benzimidazole	Benzimidazole
Approved for humans?	Yes (parasites)	No – veterinary only	Yes (parasites)
Nobel Prize	Yes (2015)	No	No
Primary anti-cancer mechanism	PAK1/Akt/mTOR, WNT pathway, autophagy	Microtubule destabilisation, glucose pathway	Tubulin inhibition, pyruvate kinase
Human cancer trials	1 active (Phase I/II). NCI preclinical.	None registered	Several (colorectal, glioblastoma, others)
Preliminary human results	No significant benefit (ASCO 2025)	No human trial data	Mixed. Some benefit in colorectal. No effect in glioblastoma. Possible harm in one GI cancer study.
Bioavailability	Good oral absorption	Poor – major limitation	Good. Crosses blood-brain barrier.
Safety profile	Well-established over decades	Unknown in humans. Liver risk. May promote tumours.	Well-established. Mild side effects.
The Joe Tippens connection	Indirect (he used fenbendazole)	Direct – but he was also on Keytruda	None
UK access	Prescription only (POM)	Veterinary product only	Prescription (Vermox). Available via Lucio Health or integrative oncologists.

My read: Each has different strengths. Mebendazole has the most human trial data, good bioavailability, and crosses the blood-brain barrier. Ivermectin has the broadest mechanism profile – at least 15 documented pathways – and Nobel Prize-validated safety data across billions of doses. Fenbendazole’s lack of human approval and poor absorption make it the weakest on paper, though some practitioners (including Makis) include it alongside the other two.

I use all three in my protocol, rotated in blocks to prevent adaptation – mebendazole in Block 1, ivermectin and fenbendazole in Block 2. This rotation approach is aligned with Jane McLelland’s Metro Map framework, which targets cancer’s metabolic fuel pathways from multiple angles simultaneously.

If you’re a UK patient looking for a supervised starting point, Lucio Health (Dr Kuhan) prescribes many antiparasitics within a monitored metabolic protocol. The Care Oncology Clinic (CoC), where Dr Kuhan worked for a number of years, previously offered a mebendazole-based four-drug protocol, though (as I understand it) they’re currently not accepting new patients. I cover some of the repurposed drugs I’ve looked at in my off-label medications overview – I’m busy building this section out, so please bare with me if there’s nt much there yet.

---

How I Access Repurposed Drugs in the UK

If you’re a UK cancer patient and this is all making sense but you’re wondering how do I actually do this? – here’s what I did.

My metabolic protocol is primarily overseen by two people: Dr Hariharan Kuhan (MBBS BSc MRCP, Imperial College London) at Lucio Health, and Amanda King (ND, DipCNM, CIMP), a naturopath and nutritionist who specialises in integrative metabolic oncology.

Dr Kuhan is a doctor with a specialist interest in metabolic oncology who previously worked at the Care Oncology Clinic before co-founding Lucio Health. He trained at Imperial, completed a research fellowship at Barts Cancer Institute investigating metabolic pathways in cancer stem cells, and worked on early-phase clinical trials at Sarah Cannon Research Institute. He prescribes and monitors repurposed drugs for cancer patients – metformin, mebendazole, ivermectin, doxycycline, propranolol, and others – alongside conventional treatment. Lucio Health is CQC-registered, based at 10 Harley Street, and offers video consultations (initial consultation GBP 450, follow-ups GBP 225 – as at time of writing, April 2026). Jane McLelland introduced me to Hari, and I’d do the same for anyone who asked – He’s a genuine miracle worker and just all round great human too.

Amanda King handles the metabolic nutrition side – personalised diet protocols, targeted supplementation, blood panel reviews, and the strategic coordination of everything I take. She trained under Dr Nasha Winters (author of: The Metabolic Approach to Cancer) in integrative metabolic oncology and has a particular expertise in off-label drug protocols for cancer patients. Her Substack (The Metabolic Nutritionist) has over 41,000 subscribers and is one of the best resources I’ve found for evidence-based information on repurposed drugs and supplements. Together with Dr Kuhan, she co-authored Metabolic Drugs for Cancer (Empress Publishing, December 2025) – a book I’d recommend to anyone researching this space. Amanda is also just an all round amazing human being, and one of my very favourite people I’ve met on this journey of mine.

They work as a pair. Hari handles the medical prescribing and monitoring. Amanda handles the nutrition, supplements, and overall protocol design. Between them, they cover the full metabolic picture. Both are explicit that this is adjunctive – it works alongside your oncologist’s treatment, not instead of it.

Contact:

• Lucio Health: luciohealth.com / info@luciohealth.com / +44 203 023 0909
• Amanda King: themetabolicnutritionist.com / admin@amandakingnd.com

---

The Risks Nobody Talks About

Every article boosting ivermectin for cancer owes you this section.

Drug Interactions

Ivermectin is metabolised by CYP3A4 and is a P-glycoprotein substrate. Drugs that inhibit CYP3A4 (ketoconazole, itraconazole, erythromycin, and some cancer drugs) may increase ivermectin levels in your blood, potentially to unsafe concentrations.

If you’re on chemotherapy, the interaction profile is largely unknown. That’s not reassuring – it’s a gap in the evidence. I’ve written separately about what chemotherapy can and can’t do – and why understanding your conventional treatment matters before layering anything on top of it.

Dose Reality

The anticancer concentrations seen in lab studies require roughly 10 times the standard antiparasitic dose. A 2002 pharmacokinetic study (Guzzo et al., Journal of Clinical Pharmacology) showed that healthy volunteers tolerated 2 mg/kg, achieving plasma concentrations relevant to cancer research. But “tolerated by healthy volunteers” and “safe for cancer patients with compromised organ function” are not the same thing.

Self-Medication Harm

This is real. NPR reported in March 2026 that nearly half of new patients at one New Orleans oncology practice were asking about ivermectin. One Stage IV patient refused chemotherapy in favour of ivermectin and fenbendazole – their cancer spread. Paediatric oncologists at Cincinnati Children’s Hospital published a case of ivermectin-related neurotoxicity in an adolescent with metastatic bone cancer who self-medicated after seeing social media posts.

Dr Jonathan Mizrahi, an oncologist in New Orleans, described these as “the most heartbreaking” cases: “patients that we really have stuff that can help, that’s tried and true, and they’re kind of putting all their eggs in a basket that I don’t think is going to be helpful for them.”

The 20-25% Estimate

Dr Mullangi at Tennessee Oncology estimates that 20-25% of some oncology patients may already be self-medicating with ivermectin. Most aren’t telling their oncologists. That means drug interactions aren’t being monitored, and treatment decisions are being made without full information.

---

What I’d Ask My Oncologist

If you’re interested in repurposed drugs, here’s how I’d approach the conversation:

1. Be honest about what you’re researching. Your oncologist can’t help you if they don’t know. Most would rather you tell them than find out later.
2. Ask about clinics like Lucio Health. They’re CQC-registered, doctor-led, and work alongside conventional treatment. Your oncologist may not agree with the approach, but they should respect that it’s supervised and monitored.
3. Ask specifically about drug interactions. “Would ivermectin or mebendazole interact with my current regimen?” is a fair question that deserves a specific answer.
4. Ask about clinical trials. There may be relevant repurposed drug trials you can join. ClinicalTrials.gov is searchable.
5. Don’t frame it as an alternative to your treatment. Frame it as a potential addition. Most oncologists will engage with “what can I add?” more readily than “I want to stop chemo and try this instead.”

Dr Skyler Johnson at the University of Utah Huntsman Cancer Institute put it well: “We want open lines of communication with our patients.”

---

My Position on Ivermectin

I’ll be direct. I take ivermectin as part of my cancer protocol. I also take mebendazole and fenbendazole. They’re rotated in two-week blocks alongside metformin, atorvastatin, doxycycline, propranolol, and a stack of supplements – all structured around Jane McLelland’s Metro Map framework, which targets cancer’s metabolic fuel pathways simultaneously.

I do this because I believe the weight of evidence supports it – not as a standalone cure, but as one layer in a multi-pronged metabolic approach alongside conventional treatment. The preclinical data shows at least 15 distinct anti-cancer mechanisms. Dr Marik’s Cancer Care monograph synthesises over 2,000 papers making the case for repurposed drugs. The Makis-Marik MSCC paper provides a coherent theoretical framework. And practitioners like Dr Kory are publishing case series with outcomes that, while not proof, are consistent with what the lab data predicts.

Is the RCT evidence there yet? No. The one completed human trial was disappointing. And I understand why mainstream oncology won’t endorse it without that data – that’s how evidence-based medicine is supposed to work.

But here’s the reality for patients like me: we don’t have the luxury of waiting 10 years for Phase III trials. The drugs are safe (billions of doses administered), cheap (off-patent), and the mechanistic evidence is strong enough that serious institutions – the NCI, Cedars-Sinai, researchers at the Journal of Orthomolecular Medicine – are investigating. My oncologist knows what I take. My integrative team monitors it. This is a supervised, informed decision, not a gamble.

What I would never do is use ivermectin instead of conventional treatment. Or buy it online and self-medicate without medical oversight. Or tell another patient it will cure their cancer. The evidence doesn’t support any of those positions. But as an adjunctive tool within a monitored metabolic protocol? I think the case is stronger than most mainstream coverage suggests.

This space is moving fast. The NCI results are expected mid-2026. The IMA’s 500-patient observational study will eventually report. More trials are being registered. I’ll update this article as the evidence evolves.

Disclaimer

I’m not a doctor. I’m a cancer patient who reads research, asks questions, and makes informed decisions with my medical team. I use ivermectin as part of a supervised metabolic protocol alongside conventional treatment. It is not a proven cancer treatment in the RCT sense. Talk to your oncologist before changing anything about your care.

If you found this useful, sign up for The Life Organic newsletter – I share what I learn as I learn it.

---

References

1. Patel Y, Chawla J, Parmar MS. Ivermectin in Cancer Treatment. Current Oncology Reports. 2025;27(9). PMID: 40715995.
2. Tang M et al. Ivermectin, a potential anticancer drug. Pharmacological Research. 2021;163:105207. PMID: 32971268.
3. Kaur B, Blavo C, Parmar MS. Ivermectin: A Multifaceted Drug. Cureus. 2024;16(3):e56025. PMID: 38606261.
4. Juarez M et al. The multitargeted drug ivermectin. American Journal of Cancer Research. 2018;8(2):317-331. PMC5835698.
5. Dou Q et al. Ivermectin Induces Cytostatic Autophagy. Cancer Research. 2016;76(15):4457-4469.
6. Melotti A et al. Ivermectin inhibits WNT-TCF pathway. EMBO Molecular Medicine. 2014;6(10):1263-1278. PMID: 25143352.
7. Dominguez-Gomez G et al. Ivermectin as an inhibitor of cancer stem-like cells. Molecular Medicine Reports. 2018;17(2):3397-3403. PMID: 29257278.
8. Jiang L et al. Ivermectin inhibits tumor metastasis. American Journal of Cancer Research. 2022;12(10):4425-4442. PMID: 36381328.
9. Draganov D et al. Ivermectin converts cold tumors hot. NPJ Breast Cancer. 2026. PMID: 41760676.
10. Guzzo CA et al. Safety and pharmacokinetics of escalating high doses of ivermectin. Journal of Clinical Pharmacology. 2002;42(10):1122-1133. PMID: 12362927.
11. NCT05318469. Ivermectin + checkpoint inhibitors in metastatic TNBC. ClinicalTrials.gov.
12. Noguchi Y. Ivermectin takes off among cancer patients. NPR. 2 March 2026.
13. Pradhan R. NCI Studying Ivermectin’s Ability To Kill Cancer Cells. KFF Health News. 10 February 2026.
14. Wheate N. What can ivermectin actually treat? The Conversation. 24 February 2026.
15. Marik PE. Cancer Care: The Role of Repurposed Drugs and Metabolic Interventions in Treating Cancer. 2nd ed. October 2024. Independent Medical Alliance.
16. Baghli I, Makis W, Marik PE et al. Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol. Journal of Orthomolecular Medicine. 2024;39(3).
17. McLelland J. How to Starve Cancer. 2nd ed. Agenor Publishing; 2021.

Frequently Asked Questions